# EDGAR Filing Document

**Accession Number:** 0001946399
**File Stem:** 0001213900-26-009144
**Filing Date:** 2026-1
**Character Count:** 3917
**Document Hash:** f43a429837d992d800c41a26700d71b6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-009144.hdr.sgml**: 20260129

**ACCESSION NUMBER**: 0001213900-26-009144

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260129

**FILED AS OF DATE**: 20260129

**DATE AS OF CHANGE**: 20260129

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LakeShore Biopharma Co., Ltd.
- **CENTRAL INDEX KEY:** 0001946399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41598
- **FILM NUMBER:** 26574779

**BUSINESS ADDRESS:**
- **STREET 1:** BUILDING NO. 2, 38 YONGDA ROAD
- **STREET 2:** DAXING BIOMEDICAL INDUSTRY PARK
- **CITY:** DAXING DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 102629
- **BUSINESS PHONE:** 17327133678

**MAIL ADDRESS:**
- **STREET 1:** BUILDING NO. 2, 38 YONGDA ROAD
- **STREET 2:** DAXING BIOMEDICAL INDUSTRY PARK
- **CITY:** DAXING DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 102629

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** YS Biopharma Co., Ltd.
- **DATE OF NAME CHANGE:** 20230310

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** YishengBio Co., Ltd
- **DATE OF NAME CHANGE:** 20220912

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER<br> PURSUANT TO RULE 13a-16 OR 15d-16 UNDER<br> THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of January 2026**

**Commission file number: 001-41598**

**LAKESHORE BIOPHARMA CO., LTD**

(Exact name of registrant as specified in its charter)

**Building No. 2, 38 Yongda Road**

**Daxing Biomedical Industry Park**

**Daxing District, Beijing, PRC**

**Tel: 010-89202086**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**EXPLANATORY NOTE**

On January 21, 2026, and January 22, 2026, we received the Arbitral Awards (the "Awards") issued by the Kaifeng Arbitration Commission regarding three arbitration cases involving Liaoning Yisheng Biopharma Co., Ltd. ("Liaoning Company") and Beijing Yisheng Biotechnology Co., Ltd. ("Beijing Company"). According to the Awards, Liaoning Company is required to pay Henan Yishengyaoye Co., Ltd. and Beijing Yisheng Xingye Technology Co., Ltd. a total principal amount of approximately RMB446 million, and other interest and miscellaneous fees totaling more than RMB36 million; Beijing Company is required to pay Beijing Yisheng Xingye Technology Co., Ltd. a principal amount of approximately RMB58.5 million, and other interest and miscellaneous fees totaling approximately RMB36 million. We dispute the claims asserted by the counterparties in the arbitrations and the validity of the arbitration results. We will vigorously challenge the Awards in all possible means in relevant tribunals. On December 12, 2024, the Shenyang Municipal Public Security Bureau has initiated an investigation into the relevant actions on the grounds of "Fraudulent Litigation" and is still actively pursuing the criminal case. As previously reported, Yi Zhang, the former chairman of the Company that the Company believes had fabricated the cases, has been listed as a criminal suspect by Chinese Public Security Authorities.

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **LakeShore Biopharma Co., Ltd** | **LakeShore Biopharma Co., Ltd** |
| By: | /s/ Rachel Yu |
| Name: | Rachel Yu |
| Title: | Director and Chief Financial Officer |

---

Date: January 29, 2026